News
MDCLF
9.70
NaN%
--
MedinCell downgraded to Hold from Buy at Kepler Cheuvreux
TipRanks · 10/14 20:35
MedinCell Delays Half-Year 2026 Earnings Release by One Day
TipRanks · 10/14 16:43
MedinCell Bolsters Finances With €41.8 Million in Non-Dilutive Funding
TipRanks · 10/13 16:37
Leerink Partners Sticks to Their Buy Rating for MedinCell SA (MEDCL)
TipRanks · 10/13 05:45
MedinCell Halts Euronext Trading Ahead of Market-Sensitive Announcement
TipRanks · 10/09 14:03
Medincell Gains Second FDA-Approved Antipsychotic as WELTRUZA Strengthens Long-Acting Injectable Strategy
TipRanks · 10/09 12:10
Medincell Shares Suspended on Euronext as Long-Acting Injectable Portfolio Advances
TipRanks · 10/09 08:03
MedinCell Updates Share Capital and Voting Rights as BEPO Platform Gains Global Traction
TipRanks · 10/05 16:53
Medincell Extends Postal Voting Window as Flood Alerts Hit Hérault
TipRanks · 09/30 10:37
MedinCell initiated with an Outperform at Oppenheimer
TipRanks · 09/23 13:56
MedinCell’s BEPO Platform Gains Momentum as Teva Unveils Strong Data for Long-Acting Antipsychotics
TipRanks · 09/21 07:21
MedinCell steps up investor outreach as long-acting injectable pipeline advances
TipRanks · 09/09 16:38
MedinCell Calls 2026 General Meeting, Bolsters Governance and Shareholder Engagement
TipRanks · 09/08 16:39
Medincell Strengthens Leadership with Appointment of New Chief Medical Officer
TipRanks · 09/01 16:49
MedinCell to Present CNS Strategy at Piper Sandler Symposium
TipRanks · 08/11 17:03
MedinCell Reports Updated Voting Rights as Long-Acting Injection Portfolio Expands
TipRanks · 08/05 16:40
Medincell Gains From Record UZEDY Sales and Progress of Olanzapine LAI
TipRanks · 07/29 11:33
MedinCell Files 2025/2026 Universal Registration Document With AMF
TipRanks · 07/28 18:33
MedinCell SA (MEDCL) Gets a Buy from Jefferies
TipRanks · 06/24 12:55
MedinCell Earnings Call Signals Investment-Led Transition
TipRanks · 06/24 00:01
More
Webull provides a variety of real-time MDCLF stock news. You can receive the latest news about MEDINCELL through multiple platforms. This information may help you make smarter investment decisions.
About MDCLF
Medincell SA is a France-based manufacturer of biological products and pharmaceutical preparations. The Company is focused on the development of therapeutic solutions with worldwide access. The Company works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations. Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others.